Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT
Arcutis Biotherapeutics — Q2 2025 Earnings Presentation
23 slides from Arcutis Biotherapeutics's earnings presentation, Aug 6, 2025
Slide 1: 2nd Quarter 2025 Financial Results & Business Update
2nd Quarter 2025 Financial Results & Business Update August 6, 2025
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation and the accompanying oral presentation contain those markets; our commercialization, marketing and the accompanying oral presentation are made pursuant to the forward-looking statements within the meaning of Section 27A of manufacturing capabilities and strategy;
Slide 3: Today's Speakers
Today’s Speakers Frank Watanabe Todd Edwards President & CEO Chief Commercial Officer Patrick Burnett, MD, PhD, FAAD Latha Vairavan Chief Medical Officer Chief Financial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 3
Slide 4: Speakers & Agenda: Business Review
Speakers & Agenda Business Review Frank Watanabe President & CEO ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 4
Slide 5: Arcutis: Q2 2025 Key Takeaways
Arcutis: Q2 2025 Key Takeaways Continued Commercial Execution Steroid Conversion Advancement Strong Business Fundamentals • # 1 prescribed branded topical • Increasing operational leverage • Q2 2025 net product revenue of across three major inflammatory • Continued progress towards $81.5 million for
Slide 6: Pillars of Strategy Will Sustain Near and Long-Term Growth
Pillars of Strategy Will Sustain Near and Long-Term Growth Indication Expansion • Scalp and body Commercial Dynamics PsO launch • Conversion from ZORYVE Life Cycle Management • Pediatric atopic topical steroids dermatitis (sNDA • 40+ case reports Innovative Pipeline submitted 2-5 years1; • PCP / ped
Slide 7: Humira and Dupixent Demonstrate Maximization of Franchise Potential Through Indication Expansion
Humira and Dupixent Demonstrate Maximization of Franchise Potential Through Indication Expansion Humira Dupixent • Launched with initial indication of rheumatoid arthritis in 2002 • Launched with initial indication of adult atopic dermatitis in 2017 • 11 additional indications added from 2005-2021 •
Slide 8: Speakers & Agenda: Commercial Update
Speakers & Agenda Commercial Update Todd Edwards Chief Commercial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 8
Slide 9: Strong Net Product Revenues in Q2 2025
Strong Net Product Revenues in Q2 2025 Net Product Revenues $M 81.5 • Q2 ‘25 net product revenues of $81.5M, +164% vs. prior year 65.3 * 63.8 – +28% net product revenues quarter over quarter 44.8 • Strong quarter over quarter volume growth continues – Typical seasonality anticipated to impact Q3 gro
Slide 10: Steady TRx Growth for ZORYVE Portfolio
Steady TRx Growth for ZORYVE Portfolio – Reaching ~16,500 Weekly TRx (Rolling 4-Week Basis) 15,000 Cream 0.15% (AD) Launch 12,500 TRx Growth R4 WEEK WEEKLY TRX Foam 0.3% (PsO) Foam Launch Launch 10,000 vs. Q1’25 vs. Q2’24 7,500 Q2’25 +13% +117% 5,000 2,500 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov
Slide 11: ZORYVE Foam 0.3% for Treatment of Scalp and Body Psoriasis Bolsters the ZORYVE Portfolio
ZORYVE Foam 0.3% for Treatment of Scalp and Body Psoriasis Bolsters the ZORYVE Portfolio Dynamic ZORYVE foam offers a unique treatment option for the more than half of plaque psoriasis patients with scalp involvement Sustained Volume Reliable clearance of plaques Growth Rapid and robust impact on it
Slide 12: Robust Rx Payor Reimbursement Delivering Profitable Scripts
Robust Rx Payor Reimbursement Delivering Profitable Scripts Versatile Portfolio ZORYVE Reaching Exceptional Overall Covered Prescriptions 3 National PBMs ZORYVE Cream 0.3% Covering ZORYVE Foam 0.3% ZORYVE ~80%+ Portfolio ZORYVE Cream 0.15% Prescriptions Covered by Insurance Profitable Script Pull Th
Slide 13: Tailoring to PCP Practice Dynamics & Selling Cycles
Tailoring to PCP Practice Dynamics & Selling Cycles Driving Frequency for Awareness, Trial & Usage in PCPs Implemented National Pharmacy Strategy to Ease Fulfillment Built Messaging Geared to PCPs Positive Signals from Early Adopters PCP = Primary Care Physician ©Copyright 2025. Arcutis Biotherapeut
Slide 14: ZORYVE is Unique in Dermatology, With Multiple Formulations & Indications
ZORYVE is Unique in Dermatology, With Multiple Formulations & Indications Plaque Psoriasis Seborrheic Dermatitis Atopic Dermatitis 9M Patients 10M Patients 26M Patients ZORYVE 0.3% ZORYVE 0.15% Cream Foam Cream Rapid, reliable relief anywhere Rapid itch relief Once-daily steroid-free topical Safety
Slide 15: Speakers & Agenda: R&D Update
Speakers & Agenda R&D Update Patrick Burnett, MD, PhD, FAAD Chief Medical Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 15
Slide 16: Continued Success With Clinical and Regulatory Milestones
Continued Success With Clinical and Regulatory Milestones Key Accomplishments / Milestones Indication Timing FDA Approval of ZORYVE Cream 0.3% Down to the Age of 6 Plaque PsO FDA Approval of ZORYVE Foam Down to the Age of 9 Seborrheic Dermatitis FDA Approval of ZORYVE Cream 0.15% Down to the Age of
Slide 17: We Continue to Progress ZORYVE for the Treatment of Pediatric Patients
We Continue to Progress ZORYVE for the Treatment of Pediatric Patients Atopic dermatitis affects 9.6 million children in the US; 60% develop symptoms in first year 1 2 • ZORYVE cream 0.05% for • INTEGUMENT-INFANT study treatment of atopic dermatitis initiated Q2’25 evaluating ages 2-5 October 13, 20
Slide 18: Collaborative Research Will Inform Clinical Development for Further ZORYVE Label Expansions
Collaborative Research Will Inform Clinical Development for Further ZORYVE Label Expansions Published Case Reports of ZORYVE Efficacy in Other Diseases Ph2a Palmo-plantar pustulosis Nickel-induced allergic contact dermatitis Collaborative Scrotal pruritus Chronic cutaneous lupus Research Cutaneous l
Slide 19: Efficacy of ARQ-255 in Ph 1b Does Not Meet Threshold for Advancement to Ph 2 Trial
Efficacy of ARQ-255 in Ph 1b Does Not Meet Threshold for Advancement to Ph 2 Trial Active Placebo SALT ≥50% at W12 24 * Dosing SALT SALT Comments Active Group %CFB %CFB at W12 at W12 Vehicle / Placebo Group ARQ-255-126 Topical -9.1% 1.5% Baricitinib Ph3 Oral -32%^ -6%^ FDA approved Ritlecitinib Ph2
Slide 20: Speakers & Agenda: Financial Results
Speakers & Agenda Latha Vairavan Financial Results Chief Financial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 20
Slide 21: Q2 2025 Financial Results
Q2 2025 Financial Results GAAP Reported $ Millions, Except Net Loss Per Share Q2 2025 Q2 2024 YoY Change Q1 2025 QoQ Change Product Revenues, Net $81.5 30.9 164% $63.8 28% Other Revenues 0.0 0.0 - 2.0 -100% Total Revenues $81.5 30.9 164% $65.8 24% Cost of Sales 7.5 3.5 116% 8.8 -15% R&D Expense 19.5
Slide 22: Continued Strong Cash Position
Continued Strong Cash Position $ Millions, except average shares GAAP Reported Cash Flow & Balance Sheet Data Q2 2025 Cash, cash equivalents, and marketable securities (June 30, 2025) $191.1 Net cash from operating activities 0.3 Total debt, net (June 30, 2025) 108.0 Weighted average shares outstand
Slide 23: Thank You! Q&A
Thank You! Frank Watanabe Todd Edwards President & CEO Chief Commercial Officer Patrick Burnett, MD, PhD, FAAD Latha Vairavan Chief Financial Q&A Chief Medical Officer Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 23
Arcutis Biotherapeutics — Q2 2025 Earnings Presentation on 6ix